Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: NOVARTIS FARMA
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60 mg administered every 28 days for 6 months in acromegalic patients with uncontrolled disease
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma Syndrome
The primary objective is: • To demonstrate the superiority of topical LDE225 versus vehicle in terms of treatment success in patients with NBCCS, 4 weeks after LDE225 treatment for 8 weeks or 12 we...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A study to assess how safe and efficient RLX030 is in pre-eclampsia Uno studio per valutare come RLX030 sia sicuro ed efficace nella pre-eclampsia
Part 1: To assess the maternal, fetal, and neonatal safety and tolerability of RLX030 at three doses and placebo when administered intravenously as infusion for 72 hours to women with pre-eclampsia...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety ofranibizumab 0.3 mg and 0.5 mg administered as twodosing regimens in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A one year multicenter, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of a single intravenous 5 mg dose zoledronic acid for the treatment of osteoporosis in men
The primary objectives are to demonstrate the superiority of treatment with zoledronic acid Calcium and Vitamin D relative to placebo Calcium and Vitamin D regarding the percent change of BMD at ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A Multicenter, Double-Blind,Randomized, Active Controlled Study to Compare the Effect of Long Term Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily in Drug Na?ve Patients with Type 2 Diabetes
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 t.i.d. vs. immediate release carbidopa/levodopa t.i.d. in Parkinsons disease patients requiring levodopa
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
Not available
Not available
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFECT OF 52 WEEKS TREATMENT WITH LAF237 50 MG BID TO METFORMIN UP TO 1000 MG BID IN DRUG NAIVE PATIENTS WITH TYPE 2 DIABETES
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa- 2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney
To assess the treatment effect on progression-free survival (PFS) of patients who receive RAD001 plus bevacizumab versus patients who receive IFN plus bevacizumab based on an estimation of the chance ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
Next